Skip to Main Content

Paper Details

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Front Immunol
2
2023
CD163, CD163 cells, CD8, CD8 T cell, CD8 cells, Cancer, OAC, Patients, T cell, anti-tumour immune cells, cancer, immune-inflamed TME, mRNA, oesophageal adenocarcinoma, patient, patients, peripheral blood mononuclear cell, pro-tumour immune cells, tumour, tumour-antigen specific T cells
Author NameAffiliation
Nicola WaddellQIMR Berghofer Medical Research Institute
Nicola WaddellQIMR Berghofer Medical Research Institute
  • 1 - 2

Datasets

Release 1.2